Fe Pharmaceuticals Launches US Subsidiary, Names New Independent Board Members
Fe Pharmaceuticals (Canada) has created a new US subsidiary, Fe Pharmaceuticals, to develop DIBI, a non-toxic, iron-binding copolymer, as a potent, broad-spectrum, antimicrobial agent active against bacterial and fungal infections, including drug resistant organisms,...
Chelation Partners’ Preclinical Anti-infective Polymer Improves Survival in Bacterial Sepsis
New published report highlights potential to combine DIBI with other anti-infectives for serious infectious diseases which induce sepsis Chelation Partners, a preclinical company focused on medical indications related to iron availability including infectious disease,...
Chelation Partners Announces Issuance of U.S. Patent Covering Composition of Matter for DIBI and Related Compounds for Controlling Infections
U.S. Pat. No. 10,709,784 was issued on July 14, 2020 by the U.S. Patent and Trademark Office for the composition of matter of metal chelating polymers Chelation Partners, a Canadian company focused on medical indications related to iron availability including...
Chelation Partners’ Lead COVID-19 Product Shows Promise for Sepsis
New published report highlights DIBI in development for COVID-19 and other infectious diseases Chelation Partners is a Canadian company focused on medical indications related to iron availability including infectious disease, cancer and inflammatory disorders. Its...